Table 5.

Associations of serum FGF23 levels with infectious composite event, cardiac composite event, and all-cause mortality

FGF23 pg/mlBaseline FGF23 as ExposureTime-dependent FGF23 as Exposure
Composite of First Infectious Hospitalization or Infectious Death
HR (95% CI), by QuartileHR (95% CI), by Quartile
Q1Q2Q3Q4Q1Q2Q3Q4
<724728–31153122–12923>12923<724728–31153122–12923>12923
# of Events133112134120133112134120
Model 11.00.95 (0.72–1.24)1.42 (1.06–1.89)1.57 (1.13–2.18)1.01.13 (0.86–1.49)1.34 (1.00–1.80)1.49 (1.06–2.11)
Model 21.00.91 (0.68–1.21)1.37 (1.02–1.84)1.41 (1.00–1.99)1.01.11 (0.84–1.47)1.30 (0.97–1.75)1.32 (0.93–1.88)
Model 31.00.95 (0.72–1.25)1.43 (1.07–1.91)1.59 (1.14–2.22)1.01.13 (0.86–1.49)1.35 (1.00–1.80)1.50 (1.06–2.12)
Composite of First Cardiac Hospitalization or Cardiac Death
# of Events127127140120127127140120
Model 11.01.05 (0.80–1.40)1.28 (0.96–1.71)1.49 (1.06–2.08)1.00.98 (0.74–1.29)1.24 (0.90–1.72)1.33 (1.01–1.76)
Model 21.01.06 (0.79–1.42)1.29 (0.96–1.73)1.50 (1.06–2.11)1.00.95 (0.72–1.25)1.21 (0.87–1.68)1.33 (1.01–1.75)
Model 31.01.05 (0.79–1.39)1.30 (0.97–1.73)1.52 (1.08–2.13)1.00.98 (0.75–1.29)1.26 (0.91–1.74)1.36 (1.03–1.79)
All-Cause Mortality
# of Events146147157132146147157132
Model 11.01.13 (0.85–1.48)1.32 (0.99–1.75)1.50 (1.07–2.12)1.01.13 (0.87–1.48)1.21 (0.91–1.61)1.55 (1.11–2.17)
Model 21.01.15 (0.86–1.53)1.36 (1.01–1.83)1.50 (1.06–2.14)1.01.05 (0.80–1.39)1.15 (0.86–1.53)1.27 (0.90–1.79)
Model 31.01.14 (0.86–1.50)1.32 (0.99–1.76)1.55 (1.09–2.18)1.01.13 (0.87–1.48)1.21 (0.91–1.61)1.56 (1.11–2.18)
  • Model 1:Adjusted for age, gender, race, diabetic status, history of cardiac disease, years of dialysis, smoking status, urea Kt/V, and dialysis membrane flux assignments, central catheter use, serum calcium, serum phosphorus, serum intact parathyroid hormone, serum 25-hydroxyvitamin D, and serum 1,25-dihydroxyvitamin D.

  • Model 2: Adjusted for covariates in Model 1 plus serum albumin, serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-α, and interferon-γ.

  • Model 3: Adjusted for covariates in Model 2 plus vitamin D analog administration.

  • Quartile 1 is the reference group in all models.